Related references
Note: Only part of the references are listed.Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study
Carle Paul et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis
Jillian Frieder et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)
R. G. Langley et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials
Lian Cui et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis
Jawad Bilal et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
Mamitaro Ohtsuki et al.
JOURNAL OF DERMATOLOGY (2018)
A trial to determine the effect of psoriasis treatment (adalimumab, phototherapy, and placebo) on cardiometabolic disease: The vascular inflammation in psoriasis (VIP) trial
J. M. Gelfand et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis
Anne M. Loos et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-and placebo-controlled study (CIMPACT)
Mark Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)
Alice B. Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon et al.
LANCET (2018)
Importance of assessing and adjusting for cross-study heterogeneity in network meta-analysis: a case study of psoriasis
Chris Cameron et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2018)
Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
Nathaniel Hendrix et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
Juergen Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis
F. Gomez-Garcia et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm® - and placebo-controlled trial (BRIDGE)
U. Mrowietz et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A)
K. Callis Duffin et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis
L. Puig et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study
L. Cai et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
K. Reich et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation
Ana Duarte et al.
HEALTH TECHNOLOGY ASSESSMENT (2017)
Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab
Boni E. Elewski et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2017)
Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis
Zarif K. Jabbar-Lopez et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
PASI ≤ 2 corresponds to PASI 90, irrespective of baseline severity: A post-hoc analysis of the PRIME-study
K. Reich et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis
G. Girolomoni et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials
L. Guenther et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich et al.
LANCET (2017)
Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial
M. Sticherling et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017
C. H. Smith et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Lowering Interleukin-12 Activity Improves Myocardial and Vascular Function Compared With Tumor Necrosis Factor-a Antagonism or Cyclosporine in Psoriasis
Ignatios Ikonomidis et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2017)
A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study
A. C. Q. de Vries et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study
Hidemi Nakagawa et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2016)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
K. B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Health-related quality of life in patients with psoriasis: a systematic review of the European literature
Montse Obradors et al.
QUALITY OF LIFE RESEARCH (2016)
Treatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumab
Mona Malakouti et al.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2016)
Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response
J. E. Signorovitch et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
The global burden of psoriatic skin disease
K. L. Goff et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
K. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C. Paul et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors
Anthony A. Gaspari et al.
DERMATOLOGIC THERAPY (2015)
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Richard B. Warren et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Diamant Thaci et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
Ulrich Mrowietz et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E. M. Griffiths et al.
LANCET (2015)
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
Herve Bachelez et al.
LANCET (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Kenneth B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
CCL20 and IL22 Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis A Randomized Clinical Trial
Ari M. Goldminz et al.
JAMA DERMATOLOGY (2015)
Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris
R. Gniadecki et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
PASI90 response: the new standard in therapeutic efficacy for psoriasis
L. Puig
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
C. Paul et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies
J. -M. Carrascosa et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Systematic Review of Interleukin-12, Interleukin-17, and Interleukin-23 Pathway Inhibitors for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis: Ustekinumab, Briakinumab, Tildrakizumab, Guselkumab, Secukinumab, Ixekizumab, and Brodalumab
William Tausend et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2014)
Conceptual and Technical Challenges in Network Meta-analysis
Andrea Cipriani et al.
ANNALS OF INTERNAL MEDICINE (2013)
Effects of the Tumor Necrosis Factor-α Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients With Psoriasis Results of a Randomized Controlled Trial
Robert Bissonnette et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2013)
The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)
Robert Strohal et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2013)
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
Rosa Parisi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study
K. A. Papp et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Evidence Synthesis for Decision Making 2: A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Evidence Synthesis for Decision Making 5: The Baseline Natural History Model
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Evidence Synthesis for Decision Making 3: HeterogeneitySubgroups, Meta-Regression, Bias, and Bias-Adjustment
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Evidence Synthesis for Decision Making 4: Inconsistency in Networks of Evidence Based on Randomized Controlled Trials
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta-analysis to network meta-analysis
Felix A. Achana et al.
STATISTICS IN MEDICINE (2013)
Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment
Sonia A. Lamel et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2012)
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
Atsuyuki Igarashi et al.
JOURNAL OF DERMATOLOGY (2012)
Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept
Jerry Bagel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
Kim Papp et al.
LANCET (2012)
Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
B. E. Strober et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)
J. Barker et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
A. B. Gottlieb et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)
Tsen-Fang Tsai et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2011)
Discovery and mechanism of ustekinumab A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders
Jacqueline M. Benson et al.
MABS (2011)
Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial
Hideshi Torii et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2010)
Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study
Akihiko Asahina et al.
JOURNAL OF DERMATOLOGY (2010)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Serum Levels of IL-17 and IL-22 Are Reduced by Etanercept, but not by Acitretin, in Patients with Psoriasis: a Randomized-Controlled Trial
M. Caproni et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2009)
Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial
P. Gisondi et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
J. -H. Saurat et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Clinical response to alimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
Kenneth B. Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
S Tyring et al.
LANCET (2006)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich et al.
LANCET (2005)
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
KA Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Quality of life in patients with psoriasis: A systematic literature review
J de Korte et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2004)
Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial
AB Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
A randomized trial of etanercept as monotherapy for psoriasis
AB Gottlieb et al.
ARCHIVES OF DERMATOLOGY (2003)
Etanercept as monotherapy in patients with psoriasis
CL Leonardi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Quantifying the harmful effect of psoriasis on health-related quality of life
SC Weiss et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2002)
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
U Chaudhari et al.
LANCET (2001)
WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility
DJ Lunn et al.
STATISTICS AND COMPUTING (2000)